Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches (original) (raw)

• Anand, I. S. Anemia and chronic heart failure implications and treatment options. J. Am. Coll. Cardiol. 52, 501–511 (2008).
  PubMed Google Scholar
• Groenveld, H. et al. Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 52, 818–827 (2008).
  PubMed Google Scholar
• Tang, Y. D. & Katz, S. D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 113, 2454–2461 (2006).
  PubMed Google Scholar
• Go, A. S. et al. Hemoglobin level, chronic kidney disease, and the risk of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure Outcomes and Resource Utilization (ANCHOR) Study. Circulation 113, 2713–2723 (2006).
  CAS PubMed Google Scholar
• Ezekowitz, J. A., McAlister, F. A. & Armstrong, P. W. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 107, 986–994 (2003).
  Google Scholar
• Vrtovec, B. et al. Significance of anemia in patients with advanced heart failure receiving long-term mechanical circulatory support. Eur. J. Heart Fail. 11, 1000–1004 (2009).
  PubMed Google Scholar
• Schroten, N. F. et al. High cumulative incidence of cancer in patients with cardio-renal-anaemia syndrome. Eur. J. Heart Fail. 12, 855–860 (2010).
  CAS PubMed Google Scholar
• Kalra, P. R. et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am. J. Cardiol. 91, 888–891 (2003).
  PubMed Google Scholar
• O'Meara, E. et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 21, 986–994 (2006).
  Google Scholar
• Hogenhuis, J. et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur. J. Heart Fail. 9, 787–794 (2007).
  CAS PubMed Google Scholar
• Sharma, R. et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE Trial. Eur. Heart J. 25, 1021–1028 (2004).
  CAS PubMed Google Scholar
• Mozaffarian, D., Nye, R. & levy, W. C. Anemia predicts mortality in severe heart failure. The Prospective Randomized Amlodipine survival Evaluation. J. Am. Coll. Cardiol. 41, 1933–1939 (2003).
  PubMed Google Scholar
• Okonko, D. O. & Anker, S. D. Anemia in chronic heart failure: pathogenetic mechanisms. J. Card. Fail. 10, S5–S9 (2004).
  CAS PubMed Google Scholar
• McClellan, W. M., Flanders, W. D., Langston, R. D., Jurkovitz, C. & Presley, R. Anemia and renal insufficiency are independent risk factors death among patients with congestive heart failure admitted to community hospitals: a population-based study. J. Am. Soc. Nephrol. 13, 1928–1936 (2002).
  PubMed Google Scholar
• Anand, I. S. et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive heart failure. Circulation 80, 299–305 (1989).
  CAS PubMed Google Scholar
• Westenbrink, B. D. et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur. Heart J. 28, 166–171 (2007).
  CAS PubMed Google Scholar
• Androne, A. S. et al. Hemodilution is common in patients with advanced heart failure. Circulation 107, 226–229 (2003).
  PubMed Google Scholar
• Van der Meer, P. et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112, 1743–1747 (2005).
  CAS PubMed Google Scholar
• Anand, I. S. et al. Anemia and change in haemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT Circulation 112, 1121–1127 (2005).
  CAS PubMed Google Scholar
• Komajda, M. et al. The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET. Eur. Heart J. 27, 1440–1446 (2006).
  PubMed Google Scholar
• Von Haehling, S. et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS Study. Eur. J. Heart Fail. 13, 656–663 (2011).
  PubMed Google Scholar
• Weiss, G. & Goodnough, L. T. Anemia of chronic disease. N. Engl. J. Med. 352, 1011–1023 (2005).
  CAS PubMed Google Scholar
• Westenbrink, B. D. et al. Bone marrow dysfunction in chronic heart failure patients. Eur. J. Heart Fail. 12, 676–684 (2010).
  CAS PubMed Google Scholar
• Kissel, C. K. et al. Selective functional exhaustion of haematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J. Am. Coll. Cardiol. 49, 2341–2349 (2007).
  PubMed Google Scholar
• Okonko, D. O. et al. Association of deranged adrenal steroid metabolism with anemia in chronic heart failure. Am. J. Cardiol. 96, 101–103 (2005).
  CAS PubMed Google Scholar
• Van der Meer, P. et al. Adequacy of endogenous erythropoietin levels and mortality in anemic heart failure patients. Eur. Heart J. 29, 1510–1515 (2008).
  CAS PubMed Google Scholar
• Opasich, C. et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anemia in patients with chronic heart failure. Eur. Heart J. 26, 2232–2237 (2005).
  CAS PubMed Google Scholar
• Witte, K. K. et al. Are hematinic deficiencies the cause of anemia in chronic heart failure? Am. Heart J. 147, 924–930 (2004).
  PubMed Google Scholar
• Wong, L. S. et al. Anaemia is associated with shorter telomere length in patients with chronic heart failure. Eur. J. Heart Fail. 12, 348–353 (2010).
  CAS PubMed Google Scholar
• de Silva, R. et al. Anemia, renal dysfunction, and their interaction in patients with chronic heart failure. Am. J. Cardiol. 98, 391–398 (2006).
  PubMed Google Scholar
• Nanas, J. N. et al. Etiology of anemia in patients with advanced heart failure. J. Am. Coll. Cardiol. 48, 2485–2489 (2006).
  PubMed Google Scholar
• Anker, S. D. et al. Rationale and design of Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur. J. Heart Fail. 11, 1084–1091 (2009).
  CAS PubMed PubMed Central Google Scholar
• Anker, S. D. et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Engl. J. Med. 361, 2436–2448 (2009).
  CAS PubMed Google Scholar
• González-Costello, J. & Comín-Colet, J. Iron deficiency and anemia in heart failure: understanding the FAIR-HF trial. Eur. J. Heart Fail. 12, 1159–1162 (2010).
  PubMed Google Scholar
• Jankowska, E. A. et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur. Heart J. 31, 1872–1880 (2010).
  CAS PubMed Google Scholar
• Cavill, I. Intravenous iron as adjuvant therapy: a two-edged sword? Nephrol. Dial. Transplant. 18(Suppl 8), viii24–viii28 (2003).
  CAS PubMed Google Scholar
• Silverberg, D. S, Iaina, A., Schwartz, D. & Wexler, D. Intravenous iron in heart failure: beyond targeting anemia. Curr. Heart Fail. Rep. 8, 14–21 (2011).
  CAS PubMed Google Scholar
• Van der Meer, P. et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J. Am. Coll. Cardiol. 44, 63–67 (2004).
  CAS PubMed Google Scholar
• Belonje, A. M., Voors, A. A., Van der Meer, P., Van Gilst. W. H. & Van Veldhuisen, D. J. Endogenous erythropoietin and outcome in heart failure. Circulation 121, 245–251 (2010).
  CAS PubMed Google Scholar
• Macdougall, I. C. & Eckardt, K. U. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 368, 947–953 (2006).
  CAS PubMed Google Scholar
• Silverberg, D. S. et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. 35, 1737–1744 (2000).
  CAS PubMed Google Scholar
• Silverberg, D. S. et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37, 1775–1780 (2001).
  CAS PubMed Google Scholar
• Mancini, D. M. et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe heart chronic failure. Circulation 107, 294–299 (2003).
  CAS PubMed Google Scholar
• Palazzuoli, A. et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am. Heart J. 152, 1096–1015 (2006).
  PubMed Google Scholar
• Parassis, J. T. et al. Effects of darbepoetin alfa on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. Heart J. 155, 751–757 (2008).
  Google Scholar
• Ponikowski, P. et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J. Am. Coll. Cardiol. 49, 753–762 (2007).
  CAS PubMed Google Scholar
• Van Veldhuisen, D. J. et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur. Heart J. 18, 2208–2216 (2007).
  Google Scholar
• Ghali, J. K. et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 117, 526–535 (2008).
  CAS PubMed Google Scholar
• Van der Meer, P., Groenveld, H. F., Januzzi, J. L. & Van Veldhuisen, D. J. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 95, 1309–1314 (2009).
  CAS PubMed Google Scholar
• McMurray, J. J. et al. Design of the Reduction of Events with darbepoetin alfa in Heart Failure (RED-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur. J. Heart Fail. 11, 795–801 (2009).
  CAS PubMed Google Scholar
• Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).
  CAS PubMed Google Scholar
• Drueke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071–2084 (2006).
  CAS PubMed Google Scholar
• Van Veldhuisen, D. J. & McMurray, J. J. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur. J. Heart Fail. 9, 110–112 (2007).
  CAS PubMed Google Scholar
• Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).
  PubMed Google Scholar
• Desai, A., Lewis, E., Solomon, S., McMurray, J. J. & Pfeffer, M. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur. J. Heart Fail. 12, 936–942 (2010).
  PubMed Google Scholar
• Szczech, L. A. et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 77, 239–246 (2010).
  CAS PubMed Google Scholar
• Westenbrink, B. D. et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur. Heart J. 28, 2018–2027 (2007).
  CAS PubMed Google Scholar
• De Boer, R. A., Pinto, Y. M., Van Veldhuisen, D. J. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Mircocirculation 10, 113–126 (2003).
  Google Scholar
• Lipsic, E. et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J. Am. Coll. Cardiol. 48, 2161–2167 (2006).
  CAS PubMed Google Scholar
• Voors, A. A. et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur. Heart J. 31, 2593–2600 (2010).
  CAS PubMed Google Scholar
• Binbrek, A. S., Rao, N. S., Al Khaja, N., Asseqqaf, J. & Sobel, B. E. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST-elevation acute myocardial infarction. Am. J. Cardiol. 104, 1035–1040 (2009).
  CAS PubMed Google Scholar
• Ehrenreich, H. et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8, 495–505 (2002).
  CAS PubMed PubMed Central Google Scholar
• Ehrenreich, H. et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40, e647–e656 (2009).
  CAS PubMed Google Scholar
• Van der Meer, P. et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur. J. Heart Fail. 6, 853–859 (2004).
  CAS PubMed Google Scholar
• Koury, M. J. & Bondurant, M. C. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248, 378–381 (1990).
  CAS PubMed Google Scholar
• Lipsic, E. et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur. J. Heart Fail. 10, 22–29 (2008).
  CAS PubMed Google Scholar
• Moon, C. et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J. Pharmacol. Exp. Ther. 316, 999–1005 (2006).
  CAS PubMed Google Scholar
• Ogino, A. et al. Erythropoietin receptor signalling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia. J. Am. Coll. Cardiol. 56, 1949–1958 (2010).
  CAS PubMed Google Scholar
• Klapholz, M. et al. The safety and tolerability of darbepoetin alfa in patients with anaemia and heart failure. Eur. J. Heart Fail. 11, 1071–1077 (2009).
  CAS PubMed Google Scholar
• Kazory, A. & Ross, E. A. Anemia: the point of convergence or divergence for kidney disease and heart failure. J. Am. Coll. Cardiol. 53, 639–647 (2009).
  PubMed Google Scholar
• Phrommintikul, A., Haas, S. J., Elsik, M. & Krum, H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369, 381–388 (2007).
  CAS PubMed Google Scholar
• Macdougall, I. C. & Cooper, A. C. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur. J. Clin. Invest. 35 (Suppl 3), 32–35 (2005).
  CAS PubMed Google Scholar
• Regidor, D. L. et al. Associations between changes in haemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 17, 1181–1191 (2006).
  CAS PubMed Google Scholar
• Solomon, S. D. et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N. Engl. J. Med. 363, 1146–1155 (2010).
  CAS PubMed Google Scholar
• Abraham, W. T. et al. Treatment of anemia with darbepoetin alfa in heart failure. Congest. Heart Fail. 16, 87–95 (2010).
  CAS PubMed Google Scholar
• Rossert, J., Gassmann-Mayer, C., Frei, D. & McClellan, W. Prevalence and predictors of epoetin hyporeponsiveness in chronic kidney disease patients. Nephrol. Dial. Transplant. 22, 794–800 (2007).
  PubMed Google Scholar
• Van der Putten, K. et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur. J. Heart Fail. 12, 943–950 (2010).
  CAS PubMed Google Scholar
• Dallalio, G., Law, E. & Means, R. T. Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 107, 2702–2704 (2006).
  CAS PubMed PubMed Central Google Scholar
• Streja, E. et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am. J. Kidney Dis. 52, 727–736 (2008).
  CAS PubMed PubMed Central Google Scholar
• Dahl, N. V., Henry, D. H. & Coyne, D. W. Thrombosis with erythropoietic stimulating agents- Does iron deficient erythropoiesis play a role? Semin. Dial. 21, 210–211 (2008).
  PubMed Google Scholar
• Fairbanks, V. & Beutler, E. in Williams Hematology 6th edn (ed Beutler, E.) 295–304, 447–440 (McGraw-Hill, New York, 2001).
  Google Scholar
• Dunn, L. L., Rahmanto, Y. S. & Richardson, D. R. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 17, 93–100 (2007).
  CAS PubMed Google Scholar
• Anderson, G. J. & Vulpe, C. D. Mammalian iron transport. Cell. Mol. Life Sci. 66, 3241–3261 (2009).
  CAS PubMed Google Scholar
• Cairo, G., Bernuzzi, F. & Recalcati, S. A precious metal: iron, an essential nutrient for all cells. Genes Nutr. 1, 25–39 (2006).
  CAS PubMed PubMed Central Google Scholar
• Andrews, N. C. Disorders of iron metabolism. N. Engl. J. Med. 341, 1986–1995 (1999).
  CAS PubMed Google Scholar
• Sutak, R., Lesuisse, E., Tachezy, J. & Richardson, D. R. Crusade for iron: iron uptake in unicellular eukaryocytes and its significance for virulence. Trends Microbiol. 16, 261–268 (2008).
  CAS PubMed Google Scholar
• Wilson, M. T. & Reeder, B. J. Oxygen-binding haem proteins. Exp. Physiol. 93, 128–132 (2008).
  CAS PubMed Google Scholar
• Zimmerman, M. B. & Hurrell, R. F. Nutritional iron deficiency. Lancet 370, 511–520 (2007).
  Google Scholar
• Anker, S. D. & Sharma, R. The syndrome of cardiac cachexia. Int. J. Cardiol. 85, 51–66 (2002).
  PubMed Google Scholar
• Weiss, G. Iron metabolism in the anemia of chronic disease. Biochim. Biophys. Acta 1790, 682–693 (2009).
  CAS PubMed Google Scholar
• Gisbert, J. P. & Gomollon, F. An update on iron physiology. World J. Gastroenterol. 15, 4659–4665 (2009).
  PubMed PubMed Central Google Scholar
• Dong, F. et al. Dietary iron deficiency induce ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthese and protein tyrosine nitration. Clin. Sci. (Lond.) 109, 277–286 (2005).
  CAS Google Scholar
• Brownlie, T., Utermohlen, V., Hinton, P. S. & Haas, J. D. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am. J. Clin. Nutr. 79, 437–443 (2004).
  CAS PubMed Google Scholar
• Haas, J. D. & Brownlie, T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J. Nutr. 131, 676S–690S (2001).
  CAS PubMed Google Scholar
• Handelman, G. J. & Levin, N. W. Iron anemia in human biology. A review of mechanisms. Heart Fail. Rev. 13, 393–404 (2008).
  PubMed Google Scholar
• Merck Research Laboratories, Merck & Co Inc. The Merck Manual of Diagnosis and Therapy 16th edn 1144 (Merck & Co Inc., Rahway, 1992).
• Mann, D. L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91, 988–998 (2002).
  CAS PubMed Google Scholar
• Heymans, S. et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 11, 119–129 (2009).
  CAS PubMed PubMed Central Google Scholar
• Naito, Y. et al. Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J. Hypertens. 29, 741–748 (2011).
  CAS PubMed Google Scholar
• Merle, U., Fein, E., Gehrke, S. G., Stremmel, W. & Kulaksiz, H. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 148, 2663–2668 (2007).
  CAS PubMed Google Scholar
• Matsumoto, M. et al. Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia. Circ. J. 74, 301–306 (2010).
  CAS PubMed Google Scholar
• Nicholas, G. et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc. Natl. Acad. Sci. U. S. A. 99, 4596–4601 (2002).
  Google Scholar
• Ganz, T. & Nemeth, E. Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 62, 347–360 (2011).
  CAS PubMed Google Scholar
• Nemeth, E. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090–2093 (2004).
  CAS PubMed Google Scholar
• Sunder-Plassmann, G. & Höri, W. H. Iron metabolism and iron substitution during erythropoietin therapy. Clin. Invest. 72, S11–S15 (1994).
  CAS Google Scholar
• Macdougall, I. C. et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 50, 1694–1699 (1996).
  CAS PubMed Google Scholar
• Van Wyck, D. B., Roppolo, M., Martinez, C. O., Mazey, R. M. & McMurray, S, for the United States Iron Sucrose (Venefor) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 68, 2846–2856 (2005).
  CAS PubMed Google Scholar
• Besarab, A., Hörl, W. H. & Silverberg, D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. The Oncologist 14 (Suppl 1), 22–33 (2009).
  CAS PubMed Google Scholar
• Weinberg, E. D. The hazards of iron loading. Metallomics 2, 732–740 (2010).
  CAS PubMed Google Scholar
• Sullivan, J. L. Long-term risk of increased use of intravenous iron. Lancet 370, 481–482 (2007).
  PubMed Google Scholar
• Cooper, C. E. Nitric oxide and iron proteins. Biochim. Biophys. Acta 1411, 290–309 (1999).
  CAS PubMed Google Scholar
• Comín-Colet, J. et al. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J. Card. Fail. 15, 727–735 (2009).
  PubMed Google Scholar
• Bolger, A. P. et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J. Am. Coll. Cardiol. 48, 1225–1227 (2006).
  CAS PubMed Google Scholar
• Usmanov, R. I., Zueva, E. B., Silverberg, D. S. & Shaked, M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J. Nephrol. 21, 236–242 (2008).
  CAS PubMed Google Scholar
• Toblli, J. E., Lombraña, A., Duarte, P. & Di Genarro, F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemia patients with chronic heart failure and renal insufficiency. J. Am. Coll. Cardiol. 50, 1657–1665 (2007).
  CAS PubMed Google Scholar
• Okonko, D. O. et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with chronic heart failure and iron deficiency. FERRIC-HF: a randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol. 51, 103–112 (2008).
  CAS PubMed Google Scholar